Latest Canada News

Page 7 of 179
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026
Structural Monitoring Systems remained profitable in the September quarter, but revenue, earnings and free cash flow all fell as aircraft maintenance delays weighed on avionics sales. The company also said Boeing’s FAA approval pathway for its 737NG structural monitoring application is taking longer than expected, with no revised completion date.
Victor Sage
Victor Sage
26 Oct 2026
Canadian Phosphate has completed 18 Wapiti drill holes and visually traced its phosphate Main Zone across approximately 9km, although laboratory assays are still pending. The company has also completed its Utah acquisition, reported stronger rock phosphate orders and ended September with $3.144 million in cash.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Everest Metals’ Mt Edon project has been selected as Australia’s representative site in a five-year German-funded exploration program and accepted into the European Union’s Raw Materials Mechanism. The recognition may improve access to technical expertise, strategic partners and potential financing, although no funding, offtake or development commitment was announced.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Great Bear Exploration has completed its maiden field campaign in Canada’s Northwest Territories, generating more than 200 high-priority targets ahead of planned 2027 drilling. The company ended September with $3.508 million in cash, but assays from 103 rock-chip samples are still pending and half of its airborne survey remains unfinished.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Beamtree Holdings has paired 10% recurring revenue growth with a $13.1 million non-cash impairment and a year-end debt covenant breach. The ASX-listed healthcare software company is betting that a tighter product portfolio, new leadership and FY27 execution can stabilise the balance sheet.
Victor Sage
Victor Sage
23 Oct 2026
Connexion Mobility delivered record Q1 FY27 revenue and profit as Hallam Road Automotive contributed for a full quarter. The company also began developing Hyundai Motor America’s Dealer Lot Management platform, while renewal talks with its largest disclosed OEM relationship remain unresolved.
Victor Sage
Victor Sage
22 Oct 2026
Michael Hill has started FY27 with same-store sales growth across all three markets, led by an 11.3% rise in Canada. The jewellery retailer says gross margin remains stable and expects profitable growth, but Christmas trading will determine how much of the momentum reaches earnings.
Victor Sage
Victor Sage
22 Oct 2026
Neu Horizon Uranium has completed its first major Swedish uranium exploration campaign since listing, generating more than 12,000 line kilometres of airborne data and preparing a maiden drill programme at Storvallflon. The ASX newcomer ended September with A$8.623 million in cash, while assays and target interpretations remain pending.
Maxwell Dee
Maxwell Dee
20 Oct 2026
BHP has held its FY27 production and unit-cost guidance despite a 19% year-on-year fall in first-quarter copper production, with stronger iron ore and coal output providing some balance. The mining giant also reported a 10.73 billion tonne Olympic Dam block cave Mineral Resource, although the new resource remains far from an Ore Reserve or approved mine plan.
Maxwell Dee
Maxwell Dee
20 Oct 2026
White Cliff Minerals shareholders have approved an A$8.77 million placement to Hancock Prospecting, giving the private company an expected 13.5% stake and funding a faster exploration campaign at Rae. The capital is aimed at advancing Danvers 1 towards a maiden resource while testing a much larger copper system across Nunavut.
Maxwell Dee
Maxwell Dee
19 Oct 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026

Browse the archive

Full archive